ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma

被引：0
|
作者：
Chowdhury, S. [1 ,2 ]
Feyerabend, S. [3 ]
Loriot, Y. [4 ]
Necchi, A. [5 ]
Gupta, S. [6 ]
Josephs, D. H. [7 ]
Rodriguez-Vida, A. [8 ]
Srinivas, S. [9 ]
Zakharia, Y. [10 ,11 ]
Nepert, D. [12 ]
Wride, K. [13 ]
Thomas, D. [14 ]
Loehr, A. [15 ]
Simmons, A. D. [15 ]
Grivas, P. [16 ]
机构：
[1] Guys Hosp, Med Oncol, London, England
[2] Sarah Cannon Res Inst, London, England
[3] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany
[4] Gustave Roussy, Dept Canc Med, Canc Campus, Villejuif, France
[5] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[6] Univ Utah, Huntsman Canc Inst, Genitourinary Oncol Program, Salt Lake City, UT USA
[7] Guys & St Thomas Hosp, Dept Med Oncol, London, England
[8] Hosp del Mar, Genitourinary Canc Unit, Barcelona, Spain
[9] Stanford Univ, Sch Med, Urol Oncol Clin, Stanford, CA 94305 USA
[10] Univ Iowa, Div Hematol, Iowa City, IA USA
[11] Holden Comprehens Canc Ctr, Iowa City, IA USA
[12] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[13] Clovis Oncol Inc, Biostat, Boulder, CO USA
[14] Clovis Oncol Inc, Clin Operat, Boulder, CO USA
[15] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
928TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study.
    Song, HS
    Do, YR
    Chang, HM
    Lee, KH
    Kim, YH
    Hong, DS
    Cho, JY
    Lee, KE
    Kim, SY
    Ryu, MH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 343S - 343S
  • [42] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
    Faivre, Sandrine
    Raymond, Eric
    Boucher, Eveline
    Douillard, Jean
    Lim, Ho Y.
    Kim, Jun S.
    Zappa, Magaly
    Lanzalone, Silvana
    Lin, Xun
    DePrimo, Samuel
    Harmon, Charles
    Ruiz-Garcia, Ana
    Lechuga, Maria J.
    Cheng, Ann Lii
    LANCET ONCOLOGY, 2009, 10 (08): : 794 - 800
  • [43] A DGOG open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer
    Boom, L. E.
    Ottevanger, P. B.
    Reyners, A.
    Kroep, J. R.
    Witteveen, P.
    Lalisang, R.
    Westermann, A. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma
    Agulnik, M.
    van Tine, B. A.
    Attia, S.
    Rademaker, A.
    Milhem, M.
    Okuno, S. H.
    ANNALS OF ONCOLOGY, 2018, 29 : 592 - 592
  • [45] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] A DGOG OPEN-LABEL MULTICENTER PHASE II STUDY OF PAZOPANIB IN METASTATIC AND LOCALLY ADVANCED HORMONE-RESISTANT ENDOMETRIAL CANCER
    Boom, L.
    Ottevanger, N.
    Reyner, A.
    Kroep, J.
    Witteveen, E.
    Lalisang, R.
    Westermann, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 56 - 56
  • [47] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [48] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [49] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
    Abou-Alfa, Ghassan K.
    Sahai, Vaibhav
    Hollebecque, Antoine
    Vaccaro, Gina
    Melisi, Davide
    Al-Rajabi, Raed
    Paulson, Andrew S.
    Borad, Mitesh J.
    Gallinson, David
    Murphy, Adrian G.
    Oh, Do-Youn
    Dotan, Efrat
    Catenacci, Daniel, V
    Van Cutsem, Eric
    Ji, Tao
    Lihou, Christine F.
    Zhen, Huiling
    Feliz, Luis
    Vogel, Arndt
    LANCET ONCOLOGY, 2020, 21 (05): : 671 - 684
  • [50] A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
    Apolo, Andrea B.
    Parnes, Howard L.
    Francis, Deneise C.
    Cordes, Lisa M.
    Berninger, Marilise
    Lamping, Elizabeth
    Costello, Rene
    Trepel, Jane B.
    Merino, Maria J.
    Folio, Les
    Lindenberg, Maria Liza
    Figg, William Douglas
    Steinberg, Seth M.
    Wright, John Joseph
    Madan, Ravi Amrit
    Ning, Yangmin M.
    Gulley, James L.
    Bottaro, Donald P.
    Dahut, William L.
    Agarwal, Piyush K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345